医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

InnoCare’s Orelabrutinib Recommended by China’s Clinical Diagnosis and Treatment Guidelines

2021年04月26日 PM02:39
このエントリーをはてなブックマークに追加


 

BEIJING

The 2021 edition of the Chinese Society of Clinical Oncology (CSCO) Lymphoma Diagnosis and Treatment Guidelines (hereinafter referred to as the “Guidelines”) was released recently. InnoCare’s novel BTK inhibitor orelabrutinib was listed as a Level I recommended treatment for relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and r/r mantle cell lymphoma (MCL).

In addition, for r/r diffuse large B-cell lymphoma (DLBCL), the Guidelines recommend that BTK inhibitors be considered to be used in combination with chemotherapy, and specifically mentioned that innovative drugs such as orelabrutinib be recommended for single or combinational therapy for r/r DLBCL based on preliminary efficacy in clinical studies. For primary central nervous system lymphoma (PCNSL), BTK inhibitor orelabrutinib demonstrates good blood-brain barrier penetration. The Guidelines recommend BTK inhibitors to be used in combination with chemotherapy, and specifically pointed out that orelabrutinib is expected to show efficacy in the treatment of PCNSL.

The Guidelines are aimed at further promoting the standardization of lymphoma diagnosis and treatment in China.

Professor Jun Ma, Chairman of the CSCO Board of Supervision and Director of the Harbin Institute of Hematology, said: “Lymphoma is one of the top ten most common tumors in China, and it is also the fastest growing hematological malignant tumor in recent years. The five-year survival rate of lymphoma patients in China still lags behind that of U.S. and Europe. Therefore, it is very important to standardize the diagnosis and treatment. The CSCO Guidelines not only reflect the continuous improvement of drug research and development in China, but also contribute to the standardization of lymphoma diagnosis and treatment, which will benefit patients.”

Professor Jun Zhu, Executive Director of the CSCO, Director of the Lymphoma Department of Peking University Cancer Hospital, said: “As the principal investigator of orelabrutinib, I am very pleased that orelabrutinib has been recognized by the experts and recommended by the Guidelines. As a lymphoma physician, we can provide Chinese patients with better anti-tumor drugs, so that our patients can obtain greater benefit. This is what we have been striving for.”

“Orelabrutinib was recommended by the CSCO Guidelines four months after its approval, which demonstrates the recognition for orelabrutinib by CSCO experts. With the further improvement of research and development, we believe that our lymphoma diagnosis and treatment can be further refined and standardized to better benefit patients in China.” said Dr. Jasmine Cui, co-founder, chairwoman and CEO of InnoCare.

Orelabrutinib is a novel BTK inhibitor with high target selectivity. It was approved for marketing by the National Medical Products Administration (NMPA) of China on December 25, 2020 for the treatment of patients with r/r CLL/SLL and r/r MCL.

About InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210425005035/en/

CONTACT

Media

Chunhua Lu

86-10-66609879

chunhua.lu@innocarepharma.com

Investor Relations

86-10-66609999

ir@innocarepharma.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  •  Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
  • ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
  • ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 Trial
  • 武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物
  • Masimo上市单例患者使用的rainbow® SuperSensor™